IN2014MN01420A - - Google Patents

Info

Publication number
IN2014MN01420A
IN2014MN01420A IN1420MUN2014A IN2014MN01420A IN 2014MN01420 A IN2014MN01420 A IN 2014MN01420A IN 1420MUN2014 A IN1420MUN2014 A IN 1420MUN2014A IN 2014MN01420 A IN2014MN01420 A IN 2014MN01420A
Authority
IN
India
Prior art keywords
cells
subpopulation
pbmcs
optionally
treatment
Prior art date
Application number
Inventor
Schwartz Michal Eisenbach
Ester Yoles
Ravid Shechter
Omer Miller
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IN2014MN01420A publication Critical patent/IN2014MN01420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells CD19+ cells CD56+ cells and optionally of CD16+ cells for use in treatment of CNS injury is provided.
IN1420MUN2014 2011-12-14 2012-12-13 IN2014MN01420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161570593P 2011-12-14 2011-12-14
PCT/IL2012/050522 WO2013088441A1 (en) 2011-12-14 2012-12-13 Human monocyte sub-population for treatment of central nervous system injury

Publications (1)

Publication Number Publication Date
IN2014MN01420A true IN2014MN01420A (en) 2015-04-03

Family

ID=48611950

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1420MUN2014 IN2014MN01420A (en) 2011-12-14 2012-12-13

Country Status (15)

Country Link
US (1) US9314483B2 (en)
EP (1) EP2790712B1 (en)
JP (1) JP6148679B2 (en)
KR (1) KR20140107439A (en)
CN (1) CN104159590A (en)
AU (2) AU2012354057B2 (en)
BR (1) BR112014014560A8 (en)
DK (1) DK2790712T3 (en)
ES (1) ES2604356T3 (en)
HU (1) HUE032096T2 (en)
IN (1) IN2014MN01420A (en)
MX (1) MX358589B (en)
PL (1) PL2790712T3 (en)
PT (1) PT2790712T (en)
WO (1) WO2013088441A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
CN105377273A (en) * 2013-05-22 2016-03-02 耶达研究与发展公司 Human monocyte sub-population for treatment of eye diseases and disorders
EP4177336A1 (en) * 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
US10722529B2 (en) 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease
WO2020148769A1 (en) * 2019-01-16 2020-07-23 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Biomarker for cns disease modification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
WO1998005795A1 (en) * 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
KR20100087781A (en) * 2001-11-21 2010-08-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Process for the manufacture of human mononuclear phagocytic leukocytes
EP2282748B1 (en) * 2008-03-28 2016-11-09 Stemcyte, Inc. Treatment of brain damage using umbilical cord blood cells
CN105377273A (en) * 2013-05-22 2016-03-02 耶达研究与发展公司 Human monocyte sub-population for treatment of eye diseases and disorders

Also Published As

Publication number Publication date
JP6148679B2 (en) 2017-06-14
KR20140107439A (en) 2014-09-04
AU2012354057B2 (en) 2017-08-03
DK2790712T3 (en) 2016-12-19
US20140363411A1 (en) 2014-12-11
AU2017254830A1 (en) 2017-11-16
BR112014014560A8 (en) 2017-07-04
EP2790712A4 (en) 2015-06-24
US9314483B2 (en) 2016-04-19
HUE032096T2 (en) 2017-09-28
WO2013088441A1 (en) 2013-06-20
AU2012354057A1 (en) 2014-07-31
PL2790712T3 (en) 2017-04-28
BR112014014560A2 (en) 2017-06-13
PT2790712T (en) 2016-12-02
ES2604356T3 (en) 2017-03-06
EP2790712B1 (en) 2016-08-31
MX358589B (en) 2018-08-27
CN104159590A (en) 2014-11-19
JP2015501835A (en) 2015-01-19
EP2790712A1 (en) 2014-10-22
MX2014007188A (en) 2015-09-22

Similar Documents

Publication Publication Date Title
IN2014MN01420A (en)
HRP20180959T1 (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
MX2019014009A (en) Improved methods for manufacturing adoptive cell therapies.
MY185016A (en) Progenitor cells of mesodermal lineage
EP2710139A4 (en) Analysis and sorting of motile cells
TN2013000468A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
UA104663C2 (en) Antibody binding to cd127
MA34818B1 (en) ANTI-PCSK9 ANTIBODIES AND METHODS OF USE
IN2015KN00666A (en)
EP4052681A3 (en) Accommodating intraocular lenses and methods of use
MX2009009283A (en) Engineered anti-il-23r antibodies.
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
MX2014004696A (en) Array of disposable absorbent articles.
IL276077A (en) Method of vitro fertilization with delivery of embryo transfer and use of peripheral blood mononuclear cells
GB201109238D0 (en) Antibodies
EP2736473A4 (en) An absorbent belted article wherein the belt and the absorbent pad have specific kinetic coefficients of friction
EP2593115A4 (en) Treatment of t-cell mediated immune disorders
MX358726B (en) Predictive biomarker of survival in the treatment of renal cell carcinoma.
HK1198471A1 (en) Thermally-conductive, metal-based bandages to aid in medical healing and methods of use
GB2510524A (en) Pulmonary hypertension
IN2015DN00172A (en)
MX2013012083A (en) Biomarkers for the treatment of multiple myeloma.
UA48629U (en) method for enrichment of magnetically purified CD34 positive stem hematopoietic cells
UA70181U (en) Method for immunological evaluation of effectiveness of interferon therapy in patients with skin melanoma
CA143999S (en) Diaper pail